Sally Ye

ABSTRACT Background Drug bridging immunoassays are widely employed as the standard approach for detecting anti-drug antibodies (ADAs) in the development of new biological entities. A major challenge in these assays is mitigating target interference, particularly when the soluble target exists in dimeric forms, which can result in false positive signals and compromise assay specificity.

China's COVID-19 policy went through some extraordinary developments in 2022. In December, the Chinese government made a u-turn by abandoning its zero-COVID policy and the related restrictions that had been in place for more than two years since the pandemic outbreak. Instantly, infections surged and patients overwhelmed China’s health systems.

Unlike the previous year, which was dominated by the theme of recovery, 2022 was an eventful year for the global healthcare industry. Supply chain disruptions, inflation, and shortage of healthcare staff have plagued the industry for most of the year while China’s COVID lockdowns, the Russia-Ukraine war, and the imminent global recession further added uncertainty and volatility. However, 2022 was a year of moving forward.